MINI FUTURE OPTIONSSCHEIN CALL - ELI LILLY & CO | Delayed Deutsche Boerse AG 14:04:59 17/06/2024 BST | ||
| 52.87 EUR | -0.02% |
|
| Current month | +14.04% | ||
| 1 month | +26.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 52.87 | -0.02% |
| 14/06/24 | 52.88 | +0.21% |
| 13/06/24 | 52.77 | +3.25% |
| 12/06/24 | 51.11 | -1.05% |
| 11/06/24 | 51.65 | -0.14% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 02:04 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DW9T1N |
| ISIN | DE000DW9T1N3 |
| Date issued | 06/02/2023 |
| Strike | 313.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 54.04 € |
|---|---|
| Lowest since issue | 2.32 € |
| Spread | 0.09 € |
| Spread % | 0.17% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- Certificat
